Sentry Investment Management LLC boosted its stake in shares of Humana Inc. (NYSE:HUM – Get Rating) by 48.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,271 shares of the insurance provider’s stock after buying an additional 413 shares during the quarter. Sentry Investment Management LLC’s holdings in Humana were worth $651,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Humana by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 11,181,313 shares of the insurance provider’s stock valued at $5,425,061,000 after acquiring an additional 147,619 shares during the period. State Street Corp raised its stake in shares of Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,613,554 shares of the insurance provider’s stock valued at $2,728,012,000 after acquiring an additional 53,899 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Humana by 63.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,692,255 shares of the insurance provider’s stock valued at $821,065,000 after acquiring an additional 654,681 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Humana by 0.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,126,002 shares of the insurance provider’s stock valued at $546,388,000 after acquiring an additional 5,926 shares during the period. Finally, Boston Partners increased its stake in Humana by 2.4% during the 3rd quarter. Boston Partners now owns 1,021,733 shares of the insurance provider’s stock worth $495,947,000 after buying an additional 24,003 shares during the period. 93.38% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms recently commented on HUM. Morgan Stanley lifted their price target on Humana from $620.00 to $637.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 11th. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a report on Wednesday, April 12th. Credit Suisse Group reduced their price objective on Humana from $635.00 to $575.00 and set an “outperform” rating on the stock in a research note on Monday, February 6th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $562.00 to $568.00 in a research note on Thursday, April 27th. Finally, Stephens decreased their target price on Humana from $625.00 to $590.00 and set an “overweight” rating for the company in a research note on Friday, February 3rd. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $597.37.
Insider Activity at Humana
In other Humana news, CEO Bruce D. Broussard sold 17,575 shares of the stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total transaction of $8,890,313.75. Following the transaction, the chief executive officer now owns 70,040 shares in the company, valued at $35,429,734. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Bruce D. Broussard sold 17,575 shares of the firm’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $505.85, for a total value of $8,890,313.75. Following the completion of the transaction, the chief executive officer now directly owns 70,040 shares of the company’s stock, valued at $35,429,734. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Susan M. Diamond sold 4,156 shares of the firm’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $526.28, for a total value of $2,187,219.68. Following the completion of the transaction, the chief financial officer now directly owns 3,931 shares of the company’s stock, valued at $2,068,806.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,779 shares of company stock valued at $12,117,856. 0.32% of the stock is currently owned by corporate insiders.
Humana Trading Up 0.1 %
HUM stock traded up $0.64 during mid-day trading on Monday, reaching $535.66. 374,155 shares of the stock traded hands, compared to its average volume of 1,024,066. The company has a current ratio of 1.39, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. Humana Inc. has a 52-week low of $410.87 and a 52-week high of $571.30. The company has a market cap of $66.93 billion, a P/E ratio of 21.73, a P/E/G ratio of 1.40 and a beta of 0.72. The stock’s fifty day moving average is $505.42 and its 200-day moving average is $512.51.
Humana (NYSE:HUM – Get Rating) last posted its quarterly earnings data on Wednesday, April 26th. The insurance provider reported $9.38 EPS for the quarter, beating analysts’ consensus estimates of $9.25 by $0.13. Humana had a net margin of 3.26% and a return on equity of 21.04%. The company had revenue of $26.74 billion during the quarter, compared to analyst estimates of $26.40 billion. During the same period in the prior year, the firm earned $8.04 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts expect that Humana Inc. will post 28.29 earnings per share for the current year.
Humana Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 30th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Thursday, June 29th. Humana’s payout ratio is presently 14.38%.
Humana Profile
Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.